EFFINGHAM AMBULATORY SURGERY CENTER has announced it will now offer the iStent inject® Trabecular Micro-Bypass System. Implanted at the time of cataract surgery, iStent inject is clinically proven to reduce eye pressure in adult patients with both cataracts and mild-to-moderate primary open-angle glaucoma.1
“This is an exciting option for every cataract patient in our community that is living with glaucoma,” said Dr Joe Spraul. “Glaucoma is a vision-threatening condition that can lead to blindness if left untreated. With iStent inject, we now have an advanced option that not only effectively manages eye pressure associated with glaucoma, but may also reduce our patients’ reliance on glaucoma medication.”
iStent inject includes two tiny implants, which make up the world’s smallest medical device known to be implanted in the human body. iStent inject is the latest innovation in trabecular micro-bypass devices, which have been implanted in hundreds of thousands of eyes, with more patients benefitting from this technology every day. Together, these tiny implants create two bypasses, or openings, between the front part of the eye and its natural drainage pathway, restoring the eye’s natural ability to drain fluid. In the U.S. pivotal trial, iStent inject was shown to be effective in decreasing intraocular pressure, with an excellent safety profile, few complications, and fast recovery time.1,2
“We are committed to providing the best possible care for our patients. So adding iStent inject was an easy decision for us,” said Dr Joe Spraul. “We believe this technology will benefit the patients in our community living with glaucoma.”
For more information on iStent inject or to schedule a consultation at Effingham Ophthalmology, please contact: 217-347-2933
ABOUT iStent inject
iStent inject is indicated for use in conjunction with cataract surgery for adult patients with mild to moderate primary open-angle glaucoma. Once implanted in the eye, iStent inject can effectively lower intraocular pressure and patients may experience a reduction in reliance on glaucoma medication (at discretion of eye care professional).
iStent inject works by creating a bypass between the front part of the eye and its natural drainage pathway to increase the flow of fluid. By creating a permanent bypass though the primary blockage site (trabecular meshwork), iStent inject is designed to:
- Improve the eye’s natural fluid outflow to safely lower intraocular pressure
- Work continuously to improve the natural flow of eye fluid in the eye
Recent randomized controlled trials and case studies have shown that iStent inject is an effective procedure with an excellent overall safety profile similar to that of cataract surgery alone.
INDICATION FOR USE. The iStent inject ® Trabecular Micro-Bypass System Model G2-M-IS is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma. CONTRAINDICATIONS. The iStent inject is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. MRI INFORMATION. The iStent inject is MR-Conditional, i.e., the device is safe for use in a specified MR environment under
specified conditions; please see Directions for Use (DFU) label for details. PRECAUTIONS. The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents. ADVERSE EVENTS. Common postoperative adverse events reported in the randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%). CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.
- iStent inject® Trabecular Micro-Bypass System: Directions for Use, Part # 45-0176.
- Saheb H, Ahmed I. Micro-Invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96-104.
©2018 Glaukos Corporation. iStent inject and Glaukos are registered trademarks of Glaukos Corporation. PM-US-0061